Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity

Biochemical Pharmacology

Volumn 88, Issue 1, 2014, Pages 58-65

  Mould, Emily ^a   Berry, Philip ^a   Jamieson, David ^a   Hill, Christopher ^a   Cano, Celine ^b   Tan, Niu ^a   Elliott, Sarah ^a   Durkacz, Barbara ^a   Newell, David ^a   Willmore, Elaine ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cancer; DNA PK; MDR1; Multidrug resistance; NU7441

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA DEPENDENT PROTEIN KINASE; DOXORUBICIN; DRN 1; DRN 2; ETOPOSIDE; NU 7441; NU 7742; PACLITAXEL; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE; PROTEIN SERINE THREONINE KINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DNA END JOINING REPAIR; DRUG ACCUMULATION; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG STRUCTURE; FLUORESCENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; ANIMAL CELL; CANCER INHIBITION; DOG; FEMALE; FLUORESCENCE ANALYSIS; IC50; NONHUMAN;

CANCER; DNA-PK; MDR1; MULTIDRUG RESISTANCE; NU7441;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; DNA-ACTIVATED PROTEIN KINASE; DOGS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR STRUCTURE; MORPHOLINES; P-GLYCOPROTEIN; SUBSTRATE SPECIFICITY;

EID: 84896729916     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.01.001     Document Type: Article

References (40)

1. K. Meek, S. Gupta, D.A. Ramsden, and S.P. Lees-Miller The DNA-dependent protein kinase: the director at the end Immunol Rev 200 2004 132 141 (Pubitemid 38998198)
2. R. Dip, and H. Naegeli Binding of the DNA-dependent protein kinase catalytic subunit to Holliday junctions Biochem J 381 2004 165 174 (Pubitemid 38932222)
3. J. An, Y.C. Huang, Q.Z. Xu, L.J. Zhou, Z.F. Shang, and B. Huang et al. DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression BMC Mol Biol 11 2010 18
4. R.H. Wong, I. Chang, C.S. Hudak, S. Hyun, H.Y. Kwan, and H.S. Sul A role of DNA-PK for the metabolic gene regulation in response to insulin Cell 136 2009 1056 1072
5. J. Ju, A.S. Naura, Y. Errami, M. Zerfaoui, H. Kim, and J.G. Kim et al. Phosphorylation of p50 NF-kappaB at a single serine residue by DNA-dependent protein kinase is critical for VCAM-1 expression upon TNF treatment J Biol Chem 285 2010 41152 41160
6. J.J. Leahy, B.T. Golding, R.J. Griffin, I.R. Hardcastle, C. Richardson, and L. Rigoreau et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries Bioorg Med Chem Lett 14 2004 6083 6087 (Pubitemid 39531277)
7. Y. Zhao, H.D. Thomas, M.A. Batey, I.G. Cowell, C.J. Richardson, and R.J. Griffin et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441 Cancer Res 66 2006 5354 5362 (Pubitemid 43844961)
8. M. Tavecchio, J.M. Munck, C. Cano, D.R. Newell, and N.J. Curtin Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination Cancer Chemother Pharmacol 69 2012 155 164
9. E. Willmore, S.L. Elliott, T. Mainou-Fowler, G.P. Summerfield, G.H. Jackson, and F. O'Neill et al. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia Clin Cancer Res 14 2008 3984 3992
10. K.M. Clapham, T. Rennison, G. Jones, F. Craven, J. Bardos, and B.T. Golding et al. Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives Org Biomol Chem 10 2012 6747 6757
11. C.J. Chen, J.E. Chin, K. Ueda, D.P. Clark, I. Pastan, and M.M. Gottesman et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells Cell 47 1986 381 389 (Pubitemid 17210152)
12. B.I. Sikic, G.A. Fisher, B.L. Lum, J. Halsey, L. Beketic-Oreskovic, and G. Chen Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein Cancer Chemother Pharmacol 40 Suppl. 1997 S13 S19
13. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 2002 48 58 (Pubitemid 37328807)
14. J.D. Allen, R.F. Brinkhuis, L. van Deemter, J. Wijnholds, and A.H. Schinkel Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance Cancer Res 60 2000 5761 5766
15. T. Tsuruo, H. Iida, S. Tsukagoshi, and Y. Sakurai Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res 41 1981 1967 1972 (Pubitemid 11114605)
16. T. Tsuruo, H. Iida, M. Nojiri, S. Tsukagoshi, and Y. Sakurai Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers Cancer Res 43 1983 2905 2910 (Pubitemid 13100565)
17. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat Rev Drug Discov 5 2006 219 234 (Pubitemid 43336035)
18. C. Hegedus, C. Ozvegy-Laczka, A. Apati, M. Magocsi, K. Nemet, and L. Orfi et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties Br J Pharmacol 158 2009 1153 1164
19. T. Kitazaki, M. Oka, Y. Nakamura, J. Tsurutani, S. Doi, and M. Yasunaga et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells Lung Cancer 49 2005 337 343 (Pubitemid 41139146)
20. Z. Shi, X.X. Peng, I.W. Kim, S. Shukla, Q.S. Si, and R.W. Robey et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance Cancer Res 67 2007 11012 11020 (Pubitemid 350145931)
21. C.L. Dai, A.K. Tiwari, C.P. Wu, X.D. Su, S.R. Wang, and D.G. Liu et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 Cancer Res 68 2008 7905 7914
22. Y.J. Mi, Y.J. Liang, H.B. Huang, H.Y. Zhao, C.P. Wu, and F. Wang et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters Cancer Res 70 2010 7981 7991
23. K.H. Eum, S.K. Ahn, H. Kang, and M. Lee Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells Mol Cell Biochem 372 2013 65 74
24. M. Haber, M.D. Norris, M. Kavallaris, D.R. Bell, R.A. Davey, and L. White et al. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein Cancer Res 49 1989 5281 5287 (Pubitemid 19240461)
25. R. Evers, M. Kool, L. van Deemter, H. Janssen, J. Calafat, and L.C. Oomen et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA J Clin Invest 101 1998 1310 1319 (Pubitemid 28166828)
26. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 2001 402 408 (Pubitemid 34164012)
27. T. Israels, C.W. Damen, M. Cole, N. van Geloven, A.V. Boddy, and H.N. Caron et al. Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate Eur J Cancer 46 2010 1841 1847
28. I.R. Hardcastle, X. Cockcroft, N.J. Curtin, M.D. El-Murr, J.J. Leahy, and M. Stockley et al. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach J Med Chem 48 2005 7829 7846 (Pubitemid 41698821)
29. C. Martin, J. Walker, A. Rothnie, and R. Callaghan The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models Br J Cancer 89 2003 1581 1589 (Pubitemid 37386618)
30. Z. Shi, A.K. Tiwari, S. Shukla, R.W. Robey, S. Singh, and I.W. Kim et al. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance Cancer Res 71 2011 3029 3041
31. M. Someya, K.I. Sakata, Y. Matsumoto, R.P. Kamdar, M. Kai, and M. Toyota et al. The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer Br J Cancer 104 2011 1724 1729
32. A. Riabinska, M. Daheim, G.S. Herter-Sprie, J. Winkler, C. Fritz, and M. Hallek et al. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors Sci Transl Med 5 2013 189ra78
33. R.C. Kane, A.T. Farrell, H. Saber, S. Tang, G. Williams, and J.M. Jee et al. Sorafenib for the treatment of advanced renal cell carcinoma Clin Cancer Res 12 2006 7271 7278 (Pubitemid 46095398)
34. L. Lang FDA approves sorafenib for patients with inoperable liver cancer Gastroenterology 134 2008 379 (Pubitemid 351173079)
35. A.S. Meena, A. Sharma, R. Kumari, N. Mohammad, S.V. Singh, and M.K. Bhat Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved PLoS ONE 8 2013 e61524
36. D.F. Cano-Gauci, and J.R. Riordan Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation Biochem Pharmacol 36 1987 2115 2123 (Pubitemid 17101723)
37. E.P. de Grouw, M.H. Raaijmakers, J.B. Boezeman, B.A. van der Reijden, L.T. van de Locht, and T.J. de Witte et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34? cells Leukemia 20 2006 750 754
38. E.J. Freireich, G.P. Bodey, K.B. McCredie, E.M. Hersh, E.A. Gehan, and J. Hart et al. Developmental therapy in adult acute leukemia Arch Intern Med 136 1976 1417 1421 (Pubitemid 8114992)
39. P.A. Pizzo, E.S. Henderson, and B.G. Leventhal Acute myelogenous leukemia in children: a preliminary report of combination chemotherapy J Pediatr 88 1976 125 130
40. G. Mathe, L. Schwarzenberg, P. Pouillart, R. Oldham, R. Weiner, and C. Jasmin et al. Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas Cancer 34 1974 985 992